The birth control pill has been available to women for a long time since FDA-approved it in 1960 but an oral contraceptive for men has not yet hit the market.Scientists are in look out for a male birth control pill which is as effective and acceptable like female birth control pill. But progress toward a male birth control pill has been stymied because available oral forms of testosterone cause liver inflammation and clear the body too quickly for once-daily dosing, thus requiring two doses a day.Stephanie Page, professor of medicine at the University of Washington, Seattle, Wash, and colleagues have conducted a study and found out a new birth control pill for men that appears to be safe when used daily for a month with hormone responses consistent with effective contraception. The results of the study have been presented at ENDO 2018, the Endocrine Society’s 100th annual meeting in Chicago, Ill.
According to researchers the experimental male oral contraceptive–called dimethandrolone undecanoate, or DMAU–combines activity of an androgen (male hormone) like testosterone, and a progestin, and is taken once a day like a pill for women. DMAU contains undecanoate, a long-chain fatty acid which slows this clearance required for once a day dose and is being developed by the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development.”DMAU is a major step forward in the development of a once-daily ‘male pill’,” Page said. “Many men say they would prefer a daily pill as a reversible contraceptive, rather than long-acting injections or topical gels, which are also in development.”
The study included 100 healthy men, ages 18 to 50 years, and took place at the University of Washington Medical Center and at Harbor-UCLA Medical Center in Torrance, CA (led by co-author Christina Wang, M.D.). The investigators tested three different doses of DMAU (100, 200, and 400 milligrams, or mg) and two different formulations inside the capsules (castor oil and powder). Each dose group included five subjects who were randomly assigned to receive an inactive placebo and another 12 to 15 men who received DMAU. Subjects took the drug or placebo for 28 days once daily with food. DMAU must be taken with food to be effective, Page noted.
A total of 83 men completed the study, including giving blood samples, for hormone and cholesterol testing, on the first and last days of the study.
At the highest dose of DMAU tested, 400 mg, subjects showed “marked suppression” of levels of their testosterone and two hormones required for sperm production. The low levels, Page said, are consistent with effective male contraception shown in longer-term studies.
“Despite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,” Page said.
All groups taking DMAU did have weight gain and decreases in HDL (“good”) cholesterol, both of which Page said were mild. All subjects passed safety tests, including markers of liver and kidney function.
“These promising results are unprecedented in the development of a prototype male pill,” Page said. “Longer term studies are currently under way to confirm that DMAU taken every day blocks sperm production.”
The experts feel that the ongoing research has brought them one step closer to expanding the options for male birth control, providing the world’s 7.6 billion people with a much-needed option for safe and reversible contraception.